Your browser doesn't support javascript.
loading
Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers.
Ali, Ahmed; Farid, Samar; Amin, Mona; Kassem, Mohamed; Al-Garem, Nouman; Al-Ghobashy, Medhat.
Afiliación
  • Ali A; Department of Pharmaceutics, Egyptian Russian University, Badr City, Egypt. ahmedclinicalbcps@yahoo.com.
  • Farid S; , Qualiobia, Shebeen-Elquanater, Kafr Taha, Egypt. ahmedclinicalbcps@yahoo.com.
  • Amin M; Department of Clinical Pharmacy, Cairo University, Cairo, Egypt.
  • Kassem M; Department of Internal Medicine, Cairo University, Cairo, Egypt.
  • Al-Garem N; Department of Pharmaceutics, Cairo University, Cairo, Egypt.
  • Al-Ghobashy M; Department of Internal Medicine, Cairo University, Cairo, Egypt.
Clin Drug Investig ; 36(2): 147-55, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26597181
OBJECTIVE: Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites. The objective of the present work was to study the clinical pharmacokinetic parameters of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites, which may help in dose selection and improve treatment outcome. METHOD: This was a prospective, open-label, single-dose, parallel-group study. At first, a pilot study was performed on one healthy volunteer by taking serial blood samples at scheduled time intervals to validate the method of analysis and sampling times. The full study was then conducted by selecting 12 cirrhotic patients with tense ascites in one group and taking nine blood samples. We also selected five healthy volunteers as the control group and took 11 blood samples. RESULTS: Statistically significant differences were observed between the healthy volunteer group and the patients group in the area under the concentration versus time curve (AUC0-t) and maximum plasma concentration (Cmax) values of midodrine and desglymidodrine. Based on the results of the pharmacokinetic analysis, the patient group was further subdivided into those receiving the interacting drug ranitidine (five patients) and those not receiving the interacting drug (seven patients). CONCLUSIONS: Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals. Drug monitoring, dose adjustments, and drug-drug interactions should all be considered during therapy in this vulnerable patient group.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ascitis / Profármacos / Agonistas alfa-Adrenérgicos / Cirrosis Hepática / Midodrina Tipo de estudio: Observational_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Drug Investig Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ascitis / Profármacos / Agonistas alfa-Adrenérgicos / Cirrosis Hepática / Midodrina Tipo de estudio: Observational_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Drug Investig Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2016 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Nueva Zelanda